Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotigalimab + nivolumab + ipilimumab
- Development stage
- Phase 1
- Lead developer
- Pyxis Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
sotigalimab + nivolumab + ipilimumab is an investigational combination immunotherapy regimen being evaluated for the treatment of advanced solid tumors, specifically melanoma and renal cell carcinoma. The regimen consists of sotigalimab (APX005M), a humanized IgG1 monoclonal antibody that acts as an agonist for the CD40 receptor on antigen-presenting cells; nivolumab, a monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor; and ipilimumab, a monoclonal antibody that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). By combining a CD40 agonist with dual checkpoint inhibition, the therapy aims to simultaneously activate the innate immune system and remove inhibitory brakes on T-cell activity, potentially overcoming resistance to standard-of-care immunotherapies. Clinical development for this triplet is being conducted in collaboration with Yale University.
- Other names
- APX005M + nivolumab + ipilimumab
02
Targets
CD40 (Cluster of differentiation 40 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sotigalimab + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotigalimab + nivolumab + ipilimumab.